Literature DB >> 15605210

[Patient-centered assessment of functional health in systemic sclerosis -- where are we now?].

T Sigl1, T Ewert, G Stucki.   

Abstract

Self-administered patient-centered questionnaires have been shown to be practical, reliable and valid in terms of evaluating functional limitations in rheumatic diseases. In systemic sclerosis a modified version of the HAQ and condition-specific questionnaires have been used. The Health Assessment Questionnaire (HAQ) does not comprehensively cover functional limitations in patients with systemic sclerosis. Visual Analogue Scales added to the modified HAQ reflect general and organ-specific symptoms only to some extent. The Self-administered Systemic Sclerosis Questionnaire (SySQ) includes general, organ-specific and musculoskeletal symptoms with a focus on functional limitations of the upper and lower extremities. The SySQ has not been examined longitudinally nor has it been validated cross-culturally. WHO's International Classification of Functioning, Disability and Health (ICF) could serve as a future reference framework and common language in terms of the design of new disease-specific, patient-centered, comprehensive questionnaires for systemic sclerosis as well as in the further improvement of established questionnaires.

Entities:  

Mesh:

Year:  2004        PMID: 15605210     DOI: 10.1007/s00393-004-0674-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  23 in total

1.  Application of the International Classification of Functioning, Disability and Health (ICF) in clinical practice.

Authors:  G Stucki; A Cieza; T Ewert; N Kostanjsek; S Chatterji; T Bedirhan Ustün
Journal:  Disabil Rehabil       Date:  2002-03-20       Impact factor: 3.033

Review 2.  Outcome measurement in scleroderma clinical trials.

Authors:  J E Pope; N Bellamy
Journal:  Semin Arthritis Rheum       Date:  1993-08       Impact factor: 5.532

3.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

Authors:  J F Fries; P W Spitz; D Y Young
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

Authors:  P J Clements; P A Lachenbruch; J R Seibold; B Zee; V D Steen; P Brennan; A J Silman; N Allegar; J Varga; M Massa
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

6.  Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma.

Authors:  Emi Matsuura; Akihide Ohta; Futoshi Kanegae; Yoshio Haruda; Osamu Ushiyama; Shuichi Koarada; Riko Togashi; Yoshifumi Tada; Noriaki Suzuki; Kohei Nagasawa
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

7.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

8.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

9.  Physical disability and psychosocial dysfunction in systemic lupus erythematosus.

Authors:  M C Hochberg; J D Sutton
Journal:  J Rheumatol       Date:  1988-06       Impact factor: 4.666

10.  D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

Authors:  V D Steen; T A Medsger; G P Rodnan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

View more
  2 in total

1.  [Systemic sclerosis].

Authors:  B A Michel
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

2.  [Medico-legal assessment of systemic sclerosis].

Authors:  M Graninger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.